Submission of Lists of Formulations

3510. SHRI M. KADHARSHA: Will the Minister of ENERGY be pleased to state:

(a) whether it is a fact that as per guidelines dated 9th December, 1987 every manufacturer and im porter should submit a list of for mulations alongwith specification, composition and categorisation of each within 45 days of the issuance of notification;

(b) if so, how many companies have submitted the lists;

trie) whether his Ministry has ex-have submitted the lists;

(d) if so, the names of the products which fall under schedule category as per guidelines but have been taken as non-schedule products by the companies;

(e) whether any of these companies hag increased the prices of these products;

(f) if so, the names of products, earlier price and the revised price; and

(g) what were the recommenda tions of the Kalkar Cornmittee in respect of medicines containing any of schedule drugs in finished medi cines and how these recommendations differ from the guidelines?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) The number of companies marketing drug formulations runs into several hundred. The details required in the question are, therefore, quote voluminous and, are not readily available. The time and effort required for collection of these will not commensurate with the results likely to be achieved.

(g) The recommendations of the Kelkar Committee were duly considered by the Government while issuing the DPCO, 1987. Guidelines issued by the Government are only in the nature of clarification of the provisions of DPCO.

Price Control on Hydroxzine Hcl

3511, SHRI BHUBANESWAR KALITA: Will the Minister of INDUSTRY be pleased to state:

(a) whether his Ministry has excluded Hydroxzine Hcl, Triprolidine Hcl, Dextromethorphan Hydrobre-mide, Chymotripsin from price control on the recommendations of Kalkar Committee;

(b) whether it is a fact that the sales turn-over of each of these drugs is more than 50 lakhs according to ORG;

(c) whether it i_s also a fact that the market share of each of these drugs of the leader and the follower brand is more than 95 per cent;

(d) what was the sales turn-over and market share of each of Clistin, Chymoral Forte, Alfapsin E. P. Forte, Marax, Actified, Recofast according to ORG;

(e) whether it is also a fact that his Ministry is subscribing for ORG;

(f) if so, whether his Ministry has noticied anjy variation between ORG sales turn-over and market share and Kelkar Committee data while examining; and

(g) if so, what are the details thereof?